Navigation Links
NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma
Date:3/16/2009

NCCN presented new updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma at the NCCN 14th Annual Conference on March 14. Notable updates include a new page on Thyroid Stimulating Hormone (TSH) Suppression, the expanded recommendation of small molecule kinase inhibitors, and revised procedures for evaluating thyroid nodules. Steven I. Sherman, MD, of The University of Texas M.D. Anderson Cancer Center and chair of the NCCN Guidelines Panel for Thyroid Carcinoma, presented the new NCCN Guidelines.

HOLLYWOOD, Fla., March 16 /PRNewswire-USNewswire/ -- The incidence of thyroid carcinoma is increasing faster than any other solid tumor according to Steven I. Sherman, MD, of The University of Texas M.D. Anderson Cancer Center during a recent presentation at the National Comprehensive Cancer Network's 14th Annual Conference discussing updates to the NCCN Clinical Practice Guidelines in Oncology(TM) for Thyroid Carcinoma.

"The increasing incidence of thyroid carcinoma is a worldwide phenomenon," stated Dr. Sherman as he outlined major updates to the NCCN Guidelines.

A notable addition to the NCCN Guidelines is a recommendation to consider commercially available, small molecule kinase inhibitors such as sorafenib (Nexavar(R), Bayer) or sunitinib (Sutent(R), Pfizer, Inc.) in the treatment of metastatic papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, or medullary carcinoma.

"Our primary recommendation for these patients is to investigate a clinical trial, but if one is not available or appropriate; data from clinical trials have shown that small molecule kinase inhibitors such as sorafenib and sunitinib can be effective," said Dr. Sherman.

Also new to the NCCN Guidelines is a page, Principles of Thyroid Stimulating Hormone (TSH) Suppression that provides recommendations for levothyroxine use for TSH Suppression throughout the Papillary, Follicular and Hurthle Cell Guidelines.

"Given the potential toxicities associated with TSH Suppression therapy that can have an effect on bone and heart health, it is best to use this therapy in a limited capacity," noted Sherman. "The new page in the NCCN Guidelines states that patients should be treated with the most conservative dose of hormone suppression therapy based on their level of disease plan. In addition, for those patients with recurrent thyroid carcinoma being administered TSH therapy, the NCCN Guidelines recommend decreasing the dose over time and encouraging adequate intake of calcium and vitamin D to prevent osteoporosis."

In addition, the procedures for evaluating thyroid nodules have been revised in the updated NCCN Guidelines particularly those for follicular or Hurthle cell neoplasms or for follicular lesions of undetermined significance, which cannot be diagnosed by fine needle aspiration (FNA). The diagnostic categories for FNA results have been revised in the new NCCN Guidelines and reflect recent data from the National Cancer Institute State of the Science Conference.

Dr. Sherman stressed the importance of evaluating suspicious nodules saying that, "ultrasound continues to be the single most useful imaging tool to diagnose palpable thyroid masses, however; there are no diagnostic features of a nodule that is benign."

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.

The NCCN Member Institutions are: City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Comprehensive Cancer Center, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University, Columbus, OH; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/University of Tennessee Cancer Institute, Memphis, TN; Stanford Comprehensive Cancer Center, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; UNMC Eppley Cancer Center at The Nebraska Medical Center, Omaha, NE; The University of Texas M. D. Anderson Cancer Center, Houston, TX; and Vanderbilt-Ingram Cancer Center, Nashville, TN.

For more information on NCCN, please visit www.nccn.org.


'/>"/>
SOURCE National Comprehensive Cancer Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
2. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
3. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
4. VNUS Medical Technologies Presents at William Blair Small-Cap Growth Stock Conference
5. NARSAD - Worlds Leading Mental Health Research Charity - Presents 19th Annual New York Mental Health Symposium, Oct. 19th & 20th
6. Retirement Living TV Presents Sex, Drugs and Rock N Roll
7. AviaraDx Presents at 2007 BIOCOM Investor Conference
8. NARSAD - the Worlds Leading Mental Health Research Charity - Presents 2007 Prizes for Outstanding Psychiatric Research at New York Gala, October 19th
9. California Science Center Science Matters Speakers Program Presents The Science and Ethics of Fear
10. Borgata Heart & Soul Foundation Presents Third Annual Women in Wine Event
11. SafeSmart, Inc. Presents SafetyTies to Sixth Annual MedAssets Technology Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a ... Yisrayl says this generation is a time like no other and society needs to understand ... Yisrayl says he does not want to sound like an old bible beater because religion ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements for ... Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire line ... all clients at reasonable prices. At the ECRM trade show, it had a unique ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched ... The drinks have been produced in collaboration with Zlatan Ibrahimovic and have been ... , After a successful launch in Sweden last year, the next generation sports ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account ... Word: Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, ... he went to school and at 19 years of age, he joined the Navy and ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... N.Y. , Jan. 20, 2017  Palladian ... programs, has announced the launch of an opioid ... new guidelines on opioids and helps stem the ... are often prescribed to treat chronic non-cancer pain ... despite serious risks and lack of evidence regarding ...
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product ... as Chief Medical Officer. Dr Weinberg will be based in ... ... than 17 years as a pharmaceutical and biotech executive with experience ... course of his career, he has interfaced with the US Food ...
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
Breaking Medicine Technology: